Background

Pancreatic ductal adenocarcinoma (PDAC) is the 4th to 5th most common cause of cancer related deaths in the western world and is virtually resistant to any conventional therapeutic regimens. It is thus a health problem with a major socioeconomic impact for any society. Despite enormous advances in the identification of molecular changes associated with the disease, new treatment options have not emerged. Thus, 5-year survival rates remain unchanged at a dismal 6%, the lowest for all solid tumours.